A Clonidine-Associated α-Adrenergic Hypothesis in Sleep Bruxism Pharmacotherapy: An Evidence-Anchored Target Analysis.

Authors

Deshui Li, Shanliang Sun, Hui Chen, Xiaojia Ci, Jiayi Luo, Fulan Wei

Published in

Journal of oral rehabilitation. Sep 22, 2026. Epub Sep 22, 2026.

Abstract

Sleep bruxism (SB) is a centrally regulated, arousal-related motor behaviour, but no pharmacotherapy has demonstrated reliable clinical efficacy. This study aimed to identify pathway-level signals most consistently supported by current polysomnography (PSG)-based pharmacotherapy evidence for SB.
We performed an evidence-anchored bioinformatic analysis of six drugs evaluated in randomized or controlled. Drugs were classified as effective or not-supported according to prespecified clinical efficacy criteria. Human pharmacodynamic targets were curated from GtoPdb and DrugBank, with precursor-derived metabolite targets excluded. Target convergence and Effective-versus-Not-supported contrasts were assessed using enrichment analyses with sensitivity testing across drug classification, enrichment background and retention thresholds.
Thirty-one curated pharmacodynamic targets converged on monoaminergic and GABA-A receptor systems, including adrenergic, dopaminergic, serotonergic and GABA-A receptor signalling. The Effective-versus-Not-supported contrast retained 14 Effective-side terms, all driven by α-adrenergic receptors (ADRA1A/1B/1D and ADRA2A/2B/2C). Dopamine-receptor enrichment was present in the broader target profile but was not retained in the efficacy contrast. Precursor-aware curation further showed that levodopa contributed to GPR143 rather than direct dopamine-receptor targets.
This efficacy-anchored analysis generated a clonidine-associated α-adrenergic, arousal-related pharmacological signal within the limited available evidence. The findings are more consistent with a central arousal-related hypothesis for SB pharmacotherapy than with a single motor-target or dopamine-driven treatment model, but require confirmation in contemporary PSG-based clinical studies and real-world patient populations.

PMID:
42773605
Bibliographic data and abstract were imported from PubMed on 23 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.